Results 81 to 90 of about 6,421 (186)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in solid organ transplant recipients [PDF]

Objectives: We aimed to address existing knowledge gaps regarding risk stratification, best use of diagnostic resources, optimal treatment, and general management of SARS-CoV-2 infection in solid organ transplant (SOT) recipients.
Tazza, Beatrice, Caroccia, Natascia, Toschi, Alice, Pascale, Renato, Gkrania-Klotsas, Effrosyni, Navarro, Paula Olivares, Canziani, Lorenzo Maria, Tavelli, Alessandro, Antinori, Andrea, Grossi, Paolo Antonio, Peghin, Maddalena, Tacconelli, Evelina, Palacios-Baena, Zaira Raquel, Viale, Pierluigi, Giannella, Maddalena   +14 more
core   +2 more sources

Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Dan Shen, Yinhua Gong, Yulan Qian, Jianguo Zhu, Jie Gao   +4 more
doaj   +1 more source

Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials [PDF]

Studies comparing all available strategies for the early treatment of mild-to-moderate COVID-19 during the Omicron era are lacking. We included people with mild-to-moderate COVID-19 and at high risk of progressing to severe disease attending five ...
Andreoni M., Antinori A., Carraro A., Cerva C., Cimaglia C., Coppola L., D'Abramo A., Del Borgo C., Falletta A., Fantoni M., Garattini S., Gasperin A., Gavaruzzi F., Giannico G., Girardi E., Gramigna G., Lanini S., Lepri A. C., Lichtner M., Maggi F., Marocco R., Mastroianni C. M., Mastrorosa I., Matteini E., Matusali G., Mazzotta V., Meschi S., Milozzi E., Nicastri E., Oliva A., Piselli P., Rosati S., Rueca M., Sarmati L., Siciliano V., Torti C., Vergori A.   +36 more
core   +1 more source

Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series [PDF]

, 2023
Bonora, Stefano, Calcagno, Andrea, De Rosa, Francesco Giuseppe, Frascione, Pio Manlio Mirko, Pepe, Andrea, Ponzetta, Laura, Ranzani, Fabio Antonino, Vita, Davide   +7 more
core   +1 more source

Proceed With Caution: Drug Interaction Complicates Use of Nirmatrelvir/Ritonavir in Kidney Transplant Recipients With COVID-19 [PDF]

, 2023
Shailly, Shikha, et. al.
core   +2 more sources

Clin Infect Dis [PDF]

Background:Nirmatrelvir/ritonavir (N/R) reduces severe outcomes among patients with COVID-19; however, rebound after treatment has been reported. We compared symptom and viral dynamics in community-based individuals with COVID-19 who completed N/R and ...

core  

Management of infectious diseases in the immunocompromised host:from A-(spergillus) to C-(OVID19) [PDF]

People with weakened immune systems, especially patients with hematological malignancies, are at a higher risk for infectious diseases, which often present with severe outcomes. COVID-19 is one of these infectious diseases.
Huygens, Sammy
core   +2 more sources

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service. [PDF]

Clin Transl Sci
Libiad Y, Franck B, Tron C, Lalanne S, Boglione-Kerrien C, Taïeb F, Verdier MC, Lemaitre F.   +7 more
europepmc   +1 more source

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source